{
    "2019-05-06": [
        [
            {
                "time": "",
                "orginal_text": "医药行业2018年报及2019年一季报综述：2018Q4利润增速承压，医药子行业持续分化",
                "features": {
                    "keywords": [
                        "医药行业",
                        "2018年报",
                        "2019一季报",
                        "利润增速",
                        "子行业分化"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "上交所12问康美药业！近300亿元如何“失踪”？开尔新材半年报预增90倍；广州浪奇发力工业大麻应用；两公司遭立案调查",
                "features": {
                    "keywords": [
                        "康美药业",
                        "财务问题",
                        "开尔新材",
                        "半年报预增",
                        "工业大麻",
                        "立案调查"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "工业大麻"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "A股药企年报季结束，哪些高管、员工薪酬较高？",
                "features": {
                    "keywords": [
                        "A股药企",
                        "年报",
                        "高管薪酬",
                        "员工薪酬"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "A股疫苗龙头研发投入PK！哪些重磅疫苗最值得期待？",
                "features": {
                    "keywords": [
                        "A股疫苗",
                        "研发投入",
                        "重磅疫苗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "最新药审动态：复星又来重磅抗癌生物类似药 3个亿级产品通过评",
                "features": {
                    "keywords": [
                        "复星",
                        "抗癌生物类似药",
                        "药审动态",
                        "亿级产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "抗癌药物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "复星旅文飙近6%兼破顶 两日暂累升10.3%",
                "features": {
                    "keywords": [
                        "复星旅文",
                        "股价上涨",
                        "累计涨幅"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "旅游"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "6日公司新闻聚焦：康美药业遭监管问询 广州浪奇发力工业大麻应用",
                "features": {
                    "keywords": [
                        "康美药业",
                        "监管问询",
                        "广州浪奇",
                        "工业大麻"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "工业大麻"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "【医药-复星医药(600196)】江琦、赵磊：2019Q1点评：持续加大研发投入，归母净利润企稳小幅增长0.92%-0429",
                "features": {
                    "keywords": [
                        "复星医药",
                        "研发投入",
                        "归母净利润",
                        "小幅增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "“最贵董事长”易主 11名高管薪酬超千万",
                "features": {
                    "keywords": [
                        "董事长",
                        "高管薪酬",
                        "超千万"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "企业管理"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}